摘要
目的检测配对盒基因2（Pax2）和上皮性钙黏附蛋白（E—cadherin）在人肾细胞癌组织中的表达，以探讨二者与肾细胞癌临床病理因素的相关性及其与预后的关系。方法利用组织芯片技术构建85例肾细胞癌与35例癌旁正常肾组织芯片，应用免疫组织化学EnVision法检测Pax2和E—cadherin在肾癌及癌旁正常组织中的表达。结果Pax2在肾细胞癌中的阳性表达率[77．6％（66／85）]显著高于癌旁正常肾组织[14．3％（5／35）]，E—cadherin在肾细胞癌中的阳性表达率[30．6％（26／85）]显著低于癌旁正常肾组织[91．4％（32／35）]，差异均有统计学意义（P〈0．01）；Pax2在肾细胞癌组织中的表达与组织学分型和病理分级密切相关（P〈0．05），与肿瘤大小和临床分期无关（P〉0．05）；E—cadherin在肾细胞癌组织中的表达与肿瘤大小、组织学分型、病理分级及临床分期密切相关（P〈0．05）。生存组中E—cadherin的阳性表达率明显高于死亡组（P〈0．05）。结论Pax2和E—cadherin的表达异常可能参与了肾细胞癌的发生发展过程，联合检测两者可用于评估肾细胞癌的恶性程度和预后。
Objective To investigate the expression of paired box 2 （Pax2） and E-cadherin in human renal cell carcinoma （RCC） and their correlation with clinicopathologic parameters. Methods The RCC tissue microarrays containing 85 renal cell carcinoma specimens and 35 normal kidney tissue specimens were used to detect Pax2 and E-cadherin expressions by immunohistochemistry. Results The positive expression rate of Pax2 was 77. 6% （66/85） in RCC specimens, which was significantly higher than that in 35 normal kidney tissue specimens （ P 〈 0. 01 ）. The positive expression rate of E-cadherin was 30. 6% （26/85） in RCC specimens, which was significantly lower than that in 35 normal kidney tissue specimens （ P 〈 0.01 ）. The expression of Pax2 in RCC was significantly related to histological classification and pathological grade （ P 〈 0. 05 ）, while it was not related to the size of tumor and clinical stage （ P 〉 0. 05 ）. The expression of E-cadherin in RCC was significantly related to the size of tumor, histological classification, pathological grade and clinical stage （P 〈 0. 05 ）. The positive expression rate of E-cadherin in survival group was significantly higher than that in death group （ P 〈 0. 05）. Conclusions The abnormal expressions of Pax2 and E-cadherin may play a crucial stage in development of human RCC. Detection of the expressions of Pax2 and E-cadherin can be used in the evaluation of malignant degree and prognosis of RCC.
出处
《中国医师杂志》
CAS
2017年第2期235-238,共4页
Journal of Chinese Physician
基金
台州市科技计划项目（11ky15）
